Published in J Exp Med on September 19, 1979
Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest (1983) 2.39
Staphylococcal alpha toxin promotes blood coagulation via attack on human platelets. J Exp Med (1988) 1.79
Human platelet activation by C3a and C3a des-arg. J Exp Med (1983) 1.22
Interaction of rat platelets with Listeria monocytogenes. Infect Immun (1981) 1.03
Human complement in the arachidonic acid transformation pathway in platelets. J Exp Med (1981) 0.97
Platelet mediated complement activation. Adv Exp Med Biol (2008) 0.88
Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O). J Immunol (2013) 0.87
Properdin: a tightly regulated critical inflammatory modulator. Immunol Rev (2016) 0.85
Requirements for membrane attack complex formation and anaphylatoxins binding to collagen-activated platelets. PLoS One (2011) 0.84
Complement 3 is involved with ventilator-induced lung injury. Int Immunopharmacol (2011) 0.81
Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo. J Clin Invest (1987) 0.79
Inflammatory mediators released by complement-derived peptides. Agents Actions (1983) 0.75
Complement and clot. Blood (2017) 0.75
A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Appl Immunol (1966) 43.66
Protein purification by affinity chromatography. Derivatizations of agarose and polyacrylamide beads. J Biol Chem (1970) 19.51
ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med (1965) 15.47
ISOLATION AND DESCRIPTION OF THE FOURTH COMPONENT OF HUMAN COMPLEMENT. J Exp Med (1963) 7.42
The ninth component of human complement: isolation, description and mode of action. Immunology (1969) 2.96
The membrane attack mechanism of complement. Isolation and subunit composition of the C5b-9 complex. J Exp Med (1975) 2.32
Additional studies on human C5: development of a modified purification method and characterization of the purified product by polyacrylamide gel electrophoresis. Immunochemistry (1972) 2.10
Molecular nature of the complement lesion. Proc Natl Acad Sci U S A (1978) 2.09
Purification of the sixth and seventh component of human complement without loss of hemolytic activity. J Immunol (1976) 2.02
Iodination of the human platelet membrane. Studies of the major surface glycoprotein. J Biol Chem (1973) 1.72
Human C3 and C5: subunit structure and modifications by trypsin and C42-C423. J Immunol (1975) 1.71
C5b-9 dimer: isolation from complement lysed cells and ultrastructural identification with complement-dependent membrane lesions. J Exp Med (1979) 1.55
Subcellular platelet factor VIII antigen and von Willebrand factor. J Exp Med (1975) 1.43
The human complement system in thrombin-mediated platelet function. J Exp Med (1978) 1.36
Effect of temperature and inhibitors on serotonin-14C release from human platelets. Am J Physiol (1971) 1.21
Human platelet-initiated formation and uptake of the C5-9 complex of human complement. J Clin Invest (1976) 1.19
Platelet-dependent generation of chemotactic activity in serum. J Exp Med (1973) 1.18
The perturbation of thrombin binding to human platelets by anions. J Clin Invest (1975) 1.07
Ultrastructural lesions on the surface of platelets associated with either blood coagulation or with antibody-mediated immune injury. J Exp Med (1975) 1.04
Complement abnormalities in human disease. Hosp Pract (1978) 0.83
The perturbation of thrombin binding to human platelets by trypsin and neuraminidase. Biochim Biophys Acta (1977) 0.80
Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest (1973) 31.28
Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest (1973) 10.18
Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G. Science (1968) 7.70
Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement. J Exp Med (1967) 6.72
Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med (1967) 5.36
Combined studies of complement receptor and surface immunoglobulin-bearing cells and sheep erythrocyte rosette-forming cells in normal and leukemic human lymphocytes. J Clin Invest (1973) 5.31
Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b. J Exp Med (1973) 4.46
A molecular concept of immune cytolysis. Arch Pathol (1966) 3.90
The second component of human complement: its isolation, fragmentation by C'1 esterase, and incorporation into C'3 convertase. J Exp Med (1968) 3.71
A human 88-kD membrane glycoprotein (CD36) functions in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparum-infected erythrocytes. J Clin Invest (1989) 3.71
Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A (1997) 3.30
Isolation of the thrombospondin membrane receptor. J Clin Invest (1987) 2.87
Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci U S A (1974) 2.83
A clinical study of the lupus anticoagulant. Blood (1976) 2.81
Specificity of human lymphocyte complement receptors. J Exp Med (1975) 2.77
Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest (1992) 2.47
Contractile proteins of endothelial cells, platelets and smooth muscle. Am J Pathol (1973) 2.36
The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry (1970) 2.18
Complex formation of platelet thrombospondin with fibrinogen. J Clin Invest (1982) 2.05
Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. J Clin Invest (1982) 2.04
Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med (1986) 2.01
Thrombospondin is the endogenous lectin of human platelets. Nature (1982) 1.98
Increased vascular permeability produced by human platelet granule cationic extract. J Clin Invest (1970) 1.98
Characterization of hematopoietic cells arising on the textured surface of left ventricular assist devices. Ann Thorac Surg (1995) 1.96
Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood (1995) 1.94
Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. Blood (1994) 1.90
Binding of plasminogen to cultured human endothelial cells. J Biol Chem (1986) 1.87
Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature (1989) 1.85
Cancer and clotting--Trousseau's warning. N Engl J Med (1992) 1.78
Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody. J Exp Med (1986) 1.75
Iodination of the human platelet membrane. Studies of the major surface glycoprotein. J Biol Chem (1973) 1.72
Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med (1986) 1.68
Nonspecific complement activation by streptococcal structures. II. Properdin-independent initiation of the alternate pathway. J Exp Med (1976) 1.64
Rabbit platelet bactericidal protein. J Exp Med (1971) 1.63
Subunit structure of factor VIII antigen synthesized by cultured human endothelial cells. J Clin Invest (1975) 1.56
Thrombospondin binds to monocytes-macrophages and mediates platelet-monocyte adhesion. J Clin Invest (1987) 1.53
Drug purpura. Semin Hematol (1965) 1.53
Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator. J Clin Invest (1984) 1.52
Tumor necrosis factor-mediated release of platelet-derived growth factor from cultured endothelial cells. J Exp Med (1987) 1.50
Subcellular platelet factor VIII antigen and von Willebrand factor. J Exp Med (1975) 1.43
Complex formation of platelet thrombospondin with histidine-rich glycoprotein. J Clin Invest (1984) 1.43
Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J Exp Med (1998) 1.43
Binding of plasminogen to extracellular matrix. J Biol Chem (1986) 1.38
Isolation, purification, and partial characterization of platelet membrane glycoproteins IIb and IIIa. J Biol Chem (1981) 1.37
Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem (1991) 1.36
The human complement system in thrombin-mediated platelet function. J Exp Med (1978) 1.36
Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding. Biochem Biophys Res Commun (1992) 1.32
Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion. J Clin Invest (1989) 1.32
Macrophage plasma membranes. I. Isolation and studies on protein components. J Exp Med (1971) 1.32
Human megakaryocytes. I. Characterization of the membrane and cytoplasmic components of isolated marrow megakaryocytes. J Exp Med (1979) 1.31
Human brain glial cells synthesize thrombospondin. Proc Natl Acad Sci U S A (1986) 1.29
Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood (1981) 1.28
Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest (1987) 1.28
Immunoinhibition of ristocetin-induced platelet aggregation. J Clin Invest (1977) 1.26
Platelet thrombospondin forms a trimolecular complex with plasminogen and histidine-rich glycoprotein. J Clin Invest (1985) 1.24
Human platelet activation by C3a and C3a des-arg. J Exp Med (1983) 1.22
Characterization of human platelet vascular permeability-enhancing activity. J Clin Invest (1972) 1.20
Immunologic studies of proteins associated with subcellular fractions of normal human platelets. J Lab Clin Med (1967) 1.20
Thrombospondin: a versatile multifunctional glycoprotein. Arteriosclerosis (1986) 1.19
Increased skin permeability in preterm infants. J Pediatr (1971) 1.18
Structural analysis of human platelet membrane glycoprotein I complex. Proc Natl Acad Sci U S A (1979) 1.18
Assay for the two different types of lymphocyte complement receptors. Scand J Immunol (1976) 1.18
Production of ultrastructural membrane lesions by the fifth component of complement. J Exp Med (1971) 1.18
Studies on human platelet protease activity. J Clin Invest (1969) 1.17
Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest (1987) 1.15
Human megakaryocytes. II. Expression of platelet proteins in early marrow megakaryocytes. J Exp Med (1981) 1.14
Thrombin-induced platelet membrane glycoprotein IIb and IIIa complex formation. An electron microscope study. J Exp Med (1981) 1.13
Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation. J Biol Chem (1985) 1.12
Cellular attachment to thrombospondin. Cooperative interactions between receptor systems. J Biol Chem (1991) 1.12
Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva. J Exp Med (1998) 1.11
Complement: Increased Efficiency of the Second Component after Treatment with Iodoacetamide. Science (1965) 1.10
Macrophage plasma membrane. II. Studies on synthesis and turnover of protein constituents. J Exp Med (1971) 1.08
Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. J Clin Invest (2001) 1.08
Thrombocytopenia due to digitoxin. Demonstration of antibody and mechanisms of action. Am J Med (1966) 1.08
Transendothelial migration of CD34+ and mature hematopoietic cells: an in vitro study using a human bone marrow endothelial cell line. Blood (1997) 1.07
Studies on the proteins of human platelet membranes. J Biol Chem (1972) 1.06
Gamma-A-blood group antibodies. J Exp Med (1966) 1.06
Ultrastructure of thrombosthenin, the contractile protein of human blood platelets. Science (1967) 1.05
Human platelet membrane protein. Biochemistry (1970) 1.05
Ultrastructural lesions on the surface of platelets associated with either blood coagulation or with antibody-mediated immune injury. J Exp Med (1975) 1.04
The platelet as an inflammatory cell. Ann N Y Acad Sci (1972) 1.04
Genetic aspects of diseases of complement: an explosion. Am J Med (1975) 1.04
Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation. Blood (1983) 1.04
Platelet membrane topography: colocalization of thrombospondin and fibrinogen with the glycoprotein IIb-IIIa complex. Blood (1985) 1.03
Cardiac dysfunction caused by purified human C3a anaphylatoxin. Proc Natl Acad Sci U S A (1985) 1.03
Interaction of platelet membrane receptors with von Willebrand factor, ristocetin, and the Fc region of immunoglobulin G. J Clin Invest (1978) 1.03
Enhancement of hemolytic complement activity by treatment of human serum with iodine. J Immunol (1971) 1.02
Binding of adenosine diphosphate by isolated membranes from human platelets. J Biol Chem (1974) 1.01
Matrix plasminogen activator inhibitor. Modulation of the extracellular proteolytic environment. J Biol Chem (1988) 1.00
Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa. J Biol Chem (1996) 0.99
Thrombospondin: phenomenology to function. Prog Hemost Thromb (1989) 0.99
BMEC-1: a human bone marrow microvascular endothelial cell line with primary cell characteristics. Microvasc Res (1996) 0.98
Inherited c'2 deficiency in man: lack of immunochemically detectable c'2 protein in serums from deficient individuals. Science (1968) 0.98
Structural analysis of factor VIII antigen in von Willebrand disease. Proc Natl Acad Sci U S A (1980) 0.98
Human complement in the arachidonic acid transformation pathway in platelets. J Exp Med (1981) 0.97